Methods of assessing susceptibility to drug-induced thrombocytopenia
AssigneeUniversite Francois Rabelais
InventorsHerve Watier, Yves Gruel, Claire Pouplard
Life of this patent
Estimating the term…
Abstract
The present invention relates to assessing the FcγRIIIa-158 polymorphism in a subject in order to determine susceptibility of the subject to drug induced thrombocytopenia, as well as therapies and therapeutic compositions based on the use of this biomarker.
Claims20
1-25. (canceled)
A method comprising sequencing the FcγRIIIa receptor polypeptide or polynucleotide encoding the FcγRIIIa receptor of a subject, determining the amino acid residue at position 158 of said subject's FcγRIIIa receptor and:
- a) selecting said subject for a treatment known to induce, or suspected of being capable of inducing, anti-platelet antibodies if the subject has a phenylalanine at position 158;
- b) adjusting the treatment of said subject if the subject has a valine at position 158;
- or
- c) improving the efficacy or treatment condition or protocol of an anti-thrombotic treatment in said subject if the subject has a valine at position 158 by adjusting the treatment, of said subject.
A method of assessing the susceptibility of a subject to heparin-induced thrombocytopenia, comprising (a) determining whether the subject has antibodies to heparin/platelet factor 4 complexes and (b) determining in vitro the FCGR3A158 genotype of said subject.
Dependencies are inferred from the claim text.